Filing of Form 20-F with SEC

RNS Number : 8040Y

AstraZeneca PLC

08 March 2017

 

8 March 2017 07:00 GMT

FILING OF ANNUAL REPORT ON FORM 20-F WITH THE US SECURITIES AND EXCHANGE COMMISSION

AstraZeneca PLC (the Company) announced today that, on 7 March 2017, it filed its 2016 Annual Report on Form 20-F with the US Securities and Exchange Commission (SEC). The document is available for viewing on the SEC website at www.sec.gov and also on the Company's website at www.astrazeneca.com. The Company will send any holder of the Company's securities, upon request, a hard copy of the Company's complete audited financial statements free of charge. Requests may be made by writing to the Company Secretary, AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of Autoimmunity, Neuroscience and Infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Enquiries
Esra Erkal-Paler	UK/Global	[phone]
Vanessa Rhodes	UK/Global	[phone]
Karen Birmingham	UK/Global	[phone]
Rob Skelding	UK/Global	[phone]
Jacob Lund	Sweden	[phone]
Michele Meixell	US	[phone]
Investor Relations
Thomas Kudsk Larsen		[phone]
Craig Marks	Finance, Fixed Income, M&A	[phone]
Henry Wheeler	Oncology	[phone]
Mitchell Chan	Oncology	[phone]
Lindsey Trickett	Cardiovascular & Metabolic Diseases	[phone]
Nick Stone	Respiratory	[phone]
Christer Gruvris	Autoimmunity, Neuroscience & Infection	[phone]
US toll free		[phone]

Adrian Kemp

Company Secretary, AstraZeneca PLC

 

END

 

 

MSCSSUEFWFWSEID